1 completed, 1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow Advanced Metastatic Cancer: new trials by email Literature Review of Advanced Metastatic Cancer trials Research Report on Advanced Metastatic Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors SYS6043 - Cancer, Solid Tumor Cancer | Phase 1 | Recruiting | Conjupro Biotherapeutics, Inc. | 386 | 2026-03-03 | 2026-04-07 |
| Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer Nivolumab Monotherapy, Nivolumab and Ipilimumab and Combination for Metastatic Cancer, Nivolumab and Ipilimumab (3 mg/kg) Combination for Prostate Cancer - Advanced Metastatic Cancer, Advanced Prostate Cancer | Phase 2 | Completed | Parker Institute for Cancer Immunotherapy | 100 | 2018-10-17 | 2024-02-07 |
Breast Neoplasms (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Prostatic Neoplasms (1) · Small Cell Lung Carcinoma (1)
Adnexal Diseases (1) · Breast Diseases (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Diseases, Male (1) · Genital Neoplasms, Female (1) · Genital Neoplasms, Male (1) · Gonadal Disorders (1) · Lung Diseases (1)
Ipilimumab (1) · Nivolumab (1)
Conjupro Biotherapeutics, Inc. (1) · Parker Institute for Cancer Immunotherapy (1)
United States (2)